Article Text

PDF
15 Differential Effects of NOAC and VKA on in Vitro Test of Global Thrombotic Status
  1. Maria Niespialowska-Steuden1,
  2. Osita Okafor2,
  3. Peter Collins1,
  4. Gareth Rosser3,
  5. Manivannan Srinivasan2,
  6. Diana Adrienne Gorog1
  1. 1Imperial College
  2. 2East and North Herts NHS Trust
  3. 3Royal Brompton and Harefield NHS Foundation Trust

Abstract

Introduction The outcome of a thrombotic trigger, namely whether lasting vessel occlusion occurs or not, is determined the balance between prothrombotic properties of blood and endogenous thrombolysis. Atrial fibrillation (AF) is a major cause of stroke. Patients affected by AF are known to have enhanced thrombotic tendency. In our study we assessed the effect of novel oral anticoagulants (NOAC) and vitamin K antagonists (VKA) on global thrombotic status.

Methods Patients with AF were tested to assess global thrombotic status before and during treatment with NOAC (dabigatran n = 12, rivaroxaban n = 9) and VKA (n = 13). Thrombotic status was assessed using the point-of-care Global Thrombosis Test (GTT). This technique utilises non-anticoagulated blood and assesses the time required for thrombus formation, occlusion (OT) and the time required for endogenous thrombolysis to occur, lysis time (LT).

Results Compared to baseline, NOAC therapy resulted in a significant prolongation of OT [median 483s (25th–75th %ile: 395–556) vs. 714s (553–842), P < 0.0001] and reduction of LT [1519s (1137–1927) vs. 724s (280–1592), P = 0.032].

Compared to baseline, VKA also prolonged OT [437s (313–550) vs. 639s (575–644), P = 0.007], with no significant effect on LT [1490s (1386–3368) vs. 1778s (1493–2365), P = 0.724]. The average INR was 2.5 ± 0.6 when the second sample was taken.

The baseline thrombotic status for the NOAC and VKA group was similar [OT 483s vs. 437s P = 0.386; LT 1519s vs. 1490s, P = 0.326]. The was no significant difference in efficacy in between rivaroxaban and dabigatran and both agents prolonged OT (43 vs. 52%, P = 0.651) and reduced LT (22 vs. 56%, P = 0.917).

The CHA2DS2VASC score was similar in the NOAC and VKA groups (2.8 ± 1.6 vs. 3.1 ± 2, P = 0.636).

Conclusions The mechanism of action is different for NOAC and VKA. Both of them reduce platelet reactivity, evidenced by the prolongation of OT. NOAC, but not VKA, improve endogenous thrombolysis. This novel mechanism of action of NOAC may underpin the superiority of some NOAC in stroke reduction over VKA, but may also contribute to enhanced bleeding profiles.

  • NOAC
  • thrombosis
  • endogenous thrombolysis

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.